Video

Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Related Videos
Sagar Lonial, MD, FACP
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Alicia Morgans, MD, MPH
Paolo Tarantino, MD
Rahul Banerjee, MD, FACP
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rahul Banerjee, MD, FACP
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD